Chief Executive Officer - Martin Whitaker

Martin Whitaker, BSc PhD - Chief Executive Officer

Martin Whitaker is Chief Executive Officer of Diurnal with overall responsibility for delivering the Group's commercial objectives. Martin has over 20 years' experience in the pharmaceutical industry and has led the Diurnal team to progress the Company’s lead products, Chronocort® and Infacort®, into pivotal Phase III clinical trials. Martin is also Director of D3 Pharma Limited which has successfully commercialised Plenachol®, a high dose Vitamin D product prescribed in the UK. Previously, Martin worked for Fusion IP plc with responsibility for commercialising research from the Medical School at the University of Sheffield.  Prior to this, Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital-backed drug delivery company spun out of the University of Nottingham developing long-acting growth hormone products. Martin is a biochemist by background and has a PhD in Pharmaceutical Science from the University of Nottingham and a BSc (Hons) in Biochemistry from Bristol University. Martin also spent a year working for the pharmaceutical company, Pfizer, in Sandwich (UK). He is Honorary Professor of Medical Innovation at The University of Sheffield.

Chief Financial Officer - Richard Bungay

Richard Bungay, BSc ACA - Chief Financial Officer

Richard Bungay is Chief Financial Officer of Diurnal. Richard has over 20 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector, mostly recently as CFO and COO of Mereo BioPharma, a company focused on developing treatments for rare and specialty diseases. His prior experience includes CFO of Glide Technologies. CFO of Verona Pharma, CEO (formerly CFO) of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and finance director of the Respiratory and Inflammation therapy area at AstraZeneca. He qualified as a chartered accountant with Deloitte and has a first class degree in Chemistry from Nottingham University. 

Chief Scientific Officer - Richard Ross

Richard Ross, MBBS MD FRCP - Chief Scientific Officer

Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.

Commercial Director - Michael Withe

Michael Withe - Commercial Director

Michael Withe is Commercial Director at Diurnal with responsibility for delivering the Group’s commercial objectives. Michael has over 25 years’ experience in the pharmaceutical industry specifically Orphan Drugs and Speciality pharmaceuticals. Previously, Michael worked for Chiesi as Head of Rare Diseases with responsibility for the creation of the Global Rare Disease Franchise and commercialising the first gene therapy and Limbus Stem Cell transplantation in the western world. Prior to this, Michael worked in the area of Lysosomal Storage Disorders for Shire and BioMarin. Michael is a microbiologist by background with a postgraduate qualification in marketing.

Medical Director - John Porter

John Porter, MBBS PhD - Medical Director 

John Porter is Medical Director at Diurnal. John is a paediatric endocrinologist and has 10 years’ experience in the pharmaceutical industry. Previously, John had medical director roles at Pfizer, Novartis and GSK covering a wide portfolio of medicines in therapy areas including endocrinology, haematology, infectious disease and vaccines. John studied medicine at Oxford and Newcastle-upon-Tyne Universities, qualifying in 1995. He trained in paediatric endocrinology and diabetes and has a PhD in the genetics of paediatric diabetes.

Product Development Director - Stewart Jones

Stewart Jones - Product Developement Director

Stewart has over 25 years’ experience in CMC and programme management, spanning the fine chemicals, CMO, Biotech and BioPharmaceutical industries. Stewart’s responsibility is to ensure that all of Diurnal’s development programmes are fully integrated and to manage their progress through to successful conclusion. Prior to joining Diurnal, Stewart was at AIM listed Mereo BioPharma as Head of CMC and oversaw all manufacturing activities.  Before Mereo, Stewart was at Chroma Therapeutics for over 9 years and was responsible for the development of the clinical portfolio, all of which have been successfully licensed on.  Previously Stewart worked in the development department at Evotec (now  Aptuit) for 9 years leading teams on the manufacturing development of several different therapeutic entities from small molecules to large molecules, peptides and liquid crystals, some of which have subsequently gone on to commercial launch.  Stewart has a BSc (hons) in chemistry.